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Tyrosine kinases (TKs) are central regulators in cellular
activities and perturbations of TK signaling contribute to
oncogenesis. However, less than half of the TKs have
been thoroughly studied and a global functional analysis
of their proteomic portrait is lacking. Here we conducted
a combined approach of RNA interference (RNAi) and
stable isotope labeling with amino acids in cell culture
(SILAC)-based quantitative proteomics to decode the TK-
regulated proteome and associated signaling dynamics.
As a result, a broad proteomic repertoire modulated by
TKs was revealed, upon silencing of the 65 TKs expressed
in MCF7 breast cancer cells. This yielded 10 new distinc-
tive TK clusters according to similarity in TK-regulated
proteome, each characterized by a unique signaling sig-
nature in contrast to previous classifications. We provide
functional analyses and identify critical pathways for each
cluster based on their common downstream targets.
Analysis of different breast cancer subtypes showed dis-
tinct correlations of each cluster with clinical outcome.
From the significantly up- and down-regulated proteins,
we identified a number of markers of drug sensitivity and
resistance. These data supports the role of TKs in regu-
lating major aspects of cellular activity, but also reveals
redundancy in signaling, explaining why kinase inhibitors
alone often fail to achieve their clinical aims. The TK-
SILACepedia provides a comprehensive resource for
studying the global function of TKs in cancer. Molecular
& Cellular Proteomics 14: 10.1074/mcp.M115.048090,
2479–2492, 2015.
Cancer is a heterogeneous disease harboring aberrant
genomic alterations (1). Although extensive transcriptome
and epigenomic analyses have provided us with data at the
genetic level and their translation to specific phenotypes, a
proteomic portrait and mapping of signaling pathways in
cancer is potentially more insightful and accurate, albeit
technologically more challenging (2). Recently, mass spec-
trometry (MS)-based quantitative proteomics have been
widely applied in cancer research, allowing large scale,
robust, and confident identification of biochemical networks
implicated in cancer (3).
Stable isotope labeling with amino acids in cell culture
(SILAC)1-coupled MS analysis represents one of the most
promising comparative quantitative methods that has been
broadly employed in proteomic research generating vast
amounts of functional data (4–8). This approach enables clear
identification and quantification of protein dynamics essential
in oncogenesis and therefore has been extensive utilized in
cancer-proteome studies (9, 10). For instance, a global pro-
teomic analysis acquired by SILAC-based MS has provided
information about the protein changes related to breast tumor
progression as well as novel prognostic markers (11). A com-
prehensive phosphoproteome analysis has also been applied
to identify and quantify the dynamics in signaling networks
upon epidermal growth factor (EGF) stimulus delineating an
integrative picture of cellular regulation (5). SILAC mouse
coupled to high-resolution MS was employed to measure the
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phosphoproteomic alterations in skin cancer development
(12). Recently, the application of SILAC-based quantitative
proteomics allowed a detailed assessment of surface pro-
teome between interphase and mitosis in human cancer cells,
providing potential pharmacodynamic biomarkers for antimi-
totic cancer chemotherapy (10). Furthermore, loss-of-function
studies using genome-wide RNAi screens are a powerful tool
and have been successfully performed to identify molecular
targets as well as key regulators in biologic processes in
cancer (13–15). Therefore, combined use of RNAi and SILAC-
based quantitative proteomics would be a potentially power-
ful approach for dissecting cellular signaling in tumorigenesis.
The involvement of tyrosine kinases (TKs) in basic cellular
processes and their contribution to development and pro-
gression of diseases has been widely described (16). TK
protein abundance as well as alterations in the total and/or
phosphorylated levels of proteins encompassed in TK signal-
ing pathways can contribute to tumorigenesis (16). Given their
involvement in cancer, targeted therapy against TKs has been
one aspect of therapy that has undoubtedly improved the
clinical outcome of patients in the past decade. However,
resistance to these treatments inevitably develops, largely
because of the aberrant activation of other TKs possessing a
complementary or compensatory function (17). Furthermore,
less than half of the TKs described thus far have been thor-
oughly studied and even in these cases a global functional
analysis and understanding of their proteomic portrait is lack-
ing (18).
Here, for the first time we describe the global mapping of
TK-regulated proteome using a high throughput RNAi screen
combined with SILAC-based quantitative proteomics in
MCF7 breast cancer cells. Overall, four thousand distinct
proteins were detected and quantified in the TK-silencing
data sets showing a diverse landscape of modulated proteins.
Based on the similarity in their proteomic changes, we present
10 new distinctive clusters from the 65 TKs and ultimately
characterize a unique proteomic signature and functional por-
trait of each cluster. These data suggest that despite the
primary structural homology of kinases, their regulated pro-
teome can vary significantly and may depend on other fac-
tors, notably their dynamic interactions with other proteins.
We also present clinical associations of each cluster with
survival data in patients with different molecular breast cancer
subtypes. In addition, based on the downstream effects of the
identified TK-clusters, we identify genes that are most signif-
icantly associated with sensitivity/resistance to doxorubicin.
Our defined functional analysis of the TK-regulated proteome
supports a fundamental involvement of TKs in the major cel-
lular processes and highlights a compensatory activation in
their associated signaling. In addition to the analyses pre-
sented herein, our established database present a unique
resource that can be utilized for comparative and integrative
analyses, for inspection of function of each TK of interest, and
their associated signaling networks in cancer.
EXPERIMENTAL PROCEDURES
RNA Extraction and RT-qPCR—RNeasy kit (Qiagen, Manchester,
UK) was used to isolate total RNA. Reverse transcription was per-
formed using high capacity cDNA reverse transcription kit (Applied
Biosystems, Warrington, UK). RT-qPCR analysis was performed on a
7900HT Thermocycler (Applied Biosystems) using SYBR® Green
master mix and primers for the whole tyrosine kinase family, pur-
chased from Qiagen.
SILAC Cell Culture—To generate SILAC conditions, normal DMEM
medium deficient in arginine (R) and lysine (K) was supplemented with
stable isotope-encoded arginine and lysine as previously described
(19, 20). For “medium” labeling we used L-[13C6] arginine (R6) and
L-[2H4] lysine (K4), and for “heavy” labeling we used L-[
13C6,
15N4]
arginine (R10) and L-[13C6,
15N2] lysine (K8). For the “light” condition,
or unlabeled, L-[12C6,
14N4] arginine (R0), and L-[
12C6,
14N2] lysine (K0)
were used. Final concentrations of arginine were 84 mg/L and 146
mg/L of lysine. The tissue culture media (Dundee Cell Products,
Dundee, UK) were supplemented with 10% dialyzed fetal bovine
serum (FCS) with 10kDa MWCO, 1% (10 mg/ml) streptomycin/
(10,000 units/ml) penicillin, 2 mM glutamine, and 1 mM sodium pyru-
vate. MCF7 cells that were grown for at least seven passages prior to
this experiment.
Western Blotting—RIPA buffer (Sigma, Hertfordshire, UK) added
with fresh protease and phosphatase inhibitor was used to extract
whole cell lysates. Cell pallets were mixed thoroughly with RIPA lysis
buffer, and then incubated in ice for 15 min before centrifuging at
15,000 rpm for 15 min at 4 °C. Protein concentration was measured
by the bicinchoninic acid (BCA) protein assay (Pierce, Paisley, UK).
Lysates were heated with 5 sodium dodecyl sulfates (SDS) sample
buffer at 95 °C for 5 min before they were loaded to 10% SDS-PAGE.
Samples were then transferred to Hybond ECL super nitrocellulose
membranes (GE Healthcare). Subsequently the membranes were
blocked in TBS containing 0.1% (v/v) Tween20 and 5% (w/v) nonfat
milk for 1 h. The primary antibodies were probed with membranes
overnight at 4 °C. The membranes were then washed three times in
TBS/Tween for 15 min following incubation with HRP-conjugated
secondary antibodies (1:3000 dilution) for 60 min. The membranes
were then washed three times again and were detected with en-
hanced chemiluminescence (ECL). Films were developed using a
Konica SRX-1001A x-ray developer. Alternatively, membranes were
incubated with IRDye® Donkey anti-mouse or Donkey anti-rabbit
secondary antibodies for 60 min and visualized by Odyssey® Fc
Imaging System (LI-COR®).
RNAi Screening in MCF7 Cells—The human Tyrosine Kinase family
siRNAs from Qiagen was used. The library was supplied in a 96-well
format (Qiagen FlexiPlate) and contained a pool of two individual
verified siRNAs per well, targeting two different sequences for each
gene. The knockdown efficiencies of all siRNAs were validated by
RT-qPCR and Western blotting. For RNAi screening, MCF7 cells were
grown in SILAC medium as described above for at least seven pas-
sages and then seeded into 100 mm dishes. Subsequently, cells were
transfected with either siControl or verified siRNAs against the tyro-
sine kinases (final concentration 40 nM) and HiPerFect reagent ac-
cording to the manufacturer’s instructions (Qiagen) for 72 h in indi-
cated SILAC medium, followed by proteomic analysis.
Protein Digestion and Peptide Fractionation—Equal amounts of
protein from unlabeled and labeled samples were combined prior to
protein digestion. Briefly, samples were reduced in 10 mM dithiothre-
itol and alkylated in 50 mM iodoacetamide prior to boiling in loading
buffer, and then separated by one-dimensional SDS-PAGE (4–12%
Bis-Tris Novex mini-gel, Invitrogen, Paisley, UK) and visualized by
colloidal Coomassie staining (Novex, Invitrogen). The entire protein
gel lanes were excised and cut into 10 slices each. Every gel slice was
subjected to in-gel digestion with trypsin overnight at 37 °C. The
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resulting tryptic peptides were extracted by formic acid (1%) and
acetonitrile (CH3CN), lyophilized in a speedvac, and resuspended in
1% formic acid.
Mass Spectrometry Methods—Trypsin-digested peptides were
separated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow
LC system. On average 0.5 g was loaded with a constant flow of 5
l/min onto an Acclaim PepMap100 nanoViper C18 trap column (100
m inner-diameter, 2 cm; Themro Scientific). After trap enrichment,
peptides were eluted onto an Acclaim PepMap RSLC nanoViper, C18
column (75 m, 15 cm; Thermo Scientific) with a linear gradient of
2–40% solvent B (80% acetonitrile with 0.08% formic acid) over 65
min with a constant flow of 300 nl/min. The HPLC system was
coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-
Orbitrap Velos, Thermo Scientific) via a nano electrospray ion source
(Thermo Scientific). The spray voltage was set to 1.2 kV, and the
temperature of the heated capillary was set to 250 °C. Full-scan MS
survey spectra (m/z 335–1800) in profile mode were acquired in the
Orbitrap with a resolution of 60,000 after accumulation of 1,000,000
ions. The fifteen most intense peptide ions from the preview scan in
the Orbitrap were fragmented by collision-induced dissociation (nor-
malized collision energy, 35%; activation Q, 0.250; and activation
time, 10 ms) in the LTQ Orbitrap after the accumulation of 10,000
ions. Maximal filling times were 1000 ms for the full scans and 150 ms
for the MS/MS scans. Precursor ion charge state screening was
enabled, and all unassigned charge states as well as singly charged
species were rejected. The dynamic exclusion list was restricted to a
maximum of 500 entries with a maximum retention period of 180 s
and a relative mass window of 15 ppm. The lock mass option was
enabled for survey scans to improve mass accuracy. Data were
acquired using the Xcalibur software.
Proteome Quantification—The raw mass spectrometric data files
obtained for each experiment were collated into a single quantitated
data set using MaxQuant (1.3.0.5.) (21) and the Andromeda search
engine software (1.3.0.5.) (22). The sequence database used was
from ipi.HUMAN v.3.68 with 87,061 entries. Enzyme specificity was
set to that of trypsin, allowing for cleavage N-terminal to proline
residues and between aspartic acid and proline residues. Other pa-
rameters used were: (1) variable modifications, methionine oxidation,
protein N-acetylation, gln3 pyro-glu; (2) fixed modifications, cysteine
carbamidomethylation; (3) database: target-decoy human MaxQuant;
(4) heavy labels: R6K4 and R10K8; (5) MS/MS tolerance: FTMS-
10ppm , ITMS- 0.6 Da; (6) maximum peptide length, 6; (7) maximum
missed cleavages, 2; (8) maximum of labeled amino acids, 3; and (9)
false discovery rate, 1%. Peptide ratios were calculated for each
arginine- and/or lysine-containing peptide as the peak area of labeled
arginine/lysine divided by the peak area of nonlabeled arginine/lysine
for each single-scan mass spectrum. Peptide ratios for all arginine-
and lysine-containing peptides sequenced for each protein were av-
eraged. Data are normalized using 1/median ratio value for each
identified protein group per labeled sample. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange
Consortium (23) via the PRIDE partner repository with the data set
identifier PXD002065. Annotated spectra for all results can be
accessed using MS-Viewer (24) via the links provided from supple-
mental Table S5.
Bioinformatics and Statistical Analyses—The bioinformatic analy-
ses were performed in R (25) and SWI-Prolog (26), using Real (27) for
connecting the two systems. Specifically, the hierarchical clustering
of SILAC proteomics data after silencing TKs was performed based
on calculated distances by R’s hclust function. The complete linkage
method that aims to find similar clusters based on overall cluster
measure was used. For the correlation heatmap, we calculated and
plotted pairwise distances between tyrosine kinases according to
their protein quantification signatures. The distance metric was con-
ducted using the centered Pearson correlation.
To visualize the TK-modulated proteomics, the heatmap of quan-
tified values showing the overall pattern of regulation was displayed.
Individual proteins were plotted in either red for down-regulated pro-
teins, or white for nondifferential and nonidentified, or blue for up-
regulated proteins. Significance B test was performed to characterize
the most significantly regulated proteins after silencing of TKs (p 
0.05) (21).
For each identified cluster, GO analysis was performed at the level
2 of the three GO domains: biologic process (BP), cellular component
(CC), and molecular function (MF) (28). Furthermore, the hyper-geo-
metric test from GOstats package was used to identify GO terms that
are enriched in the deregulated genes in each cluster (29). For every
overrepresented GO term, a network connecting deregulated genes
in this GO term was drawn showing the networks among these genes
in the STRING protein–protein interactions database (30). Only edges
with a confidence value greater than 500 were included (range:
0–999). SWI-Prolog was used for the overall control of our pipeline
and the graph operations on the STRING database.
To investigate the effect of our clusters to doxorubicin sensitivity in
a panel of breast cancer cell lines, we integrated data from the cancer
cell line encyclopedia (CCLE) (31) and drug-response signature from
the genomic markers screening of drug sensitivity in cancer (GDSC)
(32). From the downstream effects (up- or down-regulated proteins) of
each cluster, expression values from CCLE for these genes were
regressed against the GDSC IC50 values for doxorubicin for breast
cancer cell lines (37 cell lines, linear regression with ANOVA 0.01).
Kaplan-Meier (KM) Plotter Analysis—KM Plotter online survival
analysis, which has massive gene expression data and survival infor-
mation of more than 3000 patients, was used (33). Gene expression
data and relapse free and overall survival information are publically
available from the Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas (TCGA). The
database is handled by a PostgreSQL server, which integrates gene
expression and clinical data simultaneously. To analyze the prognos-
tic value of a particular gene, the patient samples are split into two
groups according to quantile expressions of the proposed biomarker.
In this study, the mean expression levels of various TKs in each
classified cluster were selected. All the 65 identified TKs were exam-
ined except EPHA6 in cluster 2 and LMTK3 in cluster 6 because of
lack of data. The relevance on relapse free survival (RFS) in luminal A,
luminal B, and basal-like breast cancer was assessed. A survival
curve with the hazard ratio (HR) with 95% confidence intervals and
logrank p value is displayed.
RESULTS
Expression Profile and Silencing of the TK Family in MCF7
Cells—We initially examined the expression profile of all mem-
bers of the TK family in the MCF7 breast cancer cell line. A
quantitative RT-qPCR analysis was performed to determine
the endogenous expression levels of all 90 TKs including 58
receptor tyrosine kinases (RTKs) and 32 cytoplasmic tyrosine
kinases (CTKs). A cut-off of threshold cycle (CT) value was set
at 34.5, above which the data have a high chance of result-
ing from cross contamination or amplification of fluorescent
artifacts (using GAPDH as endogenous control housekeeping
gene with a CT value of 17). Based on this analysis, 66 TKs
expressed at variable levels with CT values ranging from 21.5
to 34.5 (supplemental Fig. S1A) were then individually si-
lenced using a siRNA library composed of two siRNAs/
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targeted gene, followed by RT-qPCR to verify the knockdown
efficiency (RNAi sequences used for each gene are shown in
supplemental Table S1). Out of 66 TKs, 65 were successfully
silenced with a decrease of 70% at the mRNA levels (sup-
plemental Fig. S1B). Further validation of the siRNA efficacy
was assessed by Western blotting on several TKs (supple-
mental Fig. S1C).
Establishing an Approach for Identification of TK Signaling
by Combined Use of Quantitative Proteomics SILAC and RNAi
Screen—Considering the documented role and involvement
of TKs in cancer signaling (16) and the fact that a complete
picture of the TK-regulated proteome is still lacking, we per-
formed a SILAC-based quantitative proteomic analysis of the
breast cancer tyrosine kinome after siRNA treatment. Prior to
application of combined use of SILAC and RNAi, we have
validated the high reproducibility, high sensitivity and high ac-
curacy of SILAC-based MS in two independent studies (19, 20).
We therefore established an approach incorporating RT-
qPCR, RNAi, SILAC-based quantitative proteomics, and
bioinformatics analysis to characterize the TKs-regulated pro-
teome (Fig. 1A–1D). Specifically, the expression profile of all
90 TKs was examined using RT-qPCR in MCF7 cells. Fur-
ther validation of the silencing efficiency of a certified RNAi
library against TKs was done by RT-qPCR and Western
blotting. After SILAC-cell labeling (as described under “Ex-
perimental Procedures”), R0K0, R6K4, and R10K8 labeled
cells were transfected with either control siRNA or a pool of
two validated siRNAs targeting two individual TKs, respec-
tively. Subsequent MS analysis was conducted and further
bioinformatic analyses were implemented to reclassify the
FIG. 1. Strategy for identification of TK signaling by combined use of SILAC-based quantitative proteomics and RNAi. A, The
expression profile of all 90 TKs was examined using RT-qPCR in MCF7 cells. B, Silencing efficiency of a certified RNAi library composed of
two siRNAs per each TK was validated by RT-PCR and Western blotting. C, MCF7 cells were then grown in either R0K0 “light” or unlabeled
medium L-[12C6,14N4] arginine (R0) and L-[12C6,14N2] lysine (K0), or R6K4 “medium” labeled L-[13C6] arginine (R6) and L-[2H4] lysine (K4),
or R10K8 “heavy” medium labeled L-[13C6, 15N4] arginine (R10) and L-[13C6, 15N2] lysine (K8). Subsequently, SILAC-based proteomic
analysis was performed after silencing each verified TKs in MCF7 cells. D, Further bioinformatic analyses were implemented to reclassify the
family of TKs and to characterize the associated functional portrait. E, Validation of the experimental approach performed in this study. Venn
graphs showing a high overlap of identified proteome between different replicates after silencing EGFR, EPHA2, MST1R, NTRK3, and RYK are
presented. F, Comparison of quantifications between different replicates after silencing EGFR, EPHA2, MST1R, NTRK3, and RYK. Correlation
analysis of the protein ratios plotted against each replicate is shown.
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family of TKs and to characterize their associated functional
portraits.
Replicates of several randomly selected TKs, including
EGFR, EPHA2, MST1R, NTRK3, and RYK were performed
following the same protocol. Approximately 80% of the pro-
teome acquired in different replicates was shown identical,
highlighting a high degree of overlap between replicates (Fig.
1E). Importantly, the quantifications between replicates were
greatly consistent shown by correlation analysis of the protein
ratios plotted against each replicate (Fig. 1F). Moreover, the
expressions of differentially regulated proteins upon silencing
of individual TKs were selectively validated using Western
blotting, further confirming the reproducibility of our data
(supplemental Fig. S2).
TKs Silencing Induces Global Proteomic Alterations in
MCF7 Cells—For each individual TK, from 27,000 nonre-
dundant peptide sequences, a SILAC-based proteome was
assembled comprising more than 2000 distinguishable and
unambiguously identified proteins with a minimum of two
peptides with a false discovery rate (FDR) of 1% (minimal
peptide length of seven amino acids). The mass spectrometry
proteomics data have been deposited to the ProteomeX-
change Consortium (23) via the PRIDE partner repository
(accession: PXD002065). Detailed information for each iden-
tified protein, including protein IDs, number of peptides used
for identification, and % coverage is also shown in supple-
mental Table S2. From these proteins, more than 2000 were
quantified and their distribution according to fold changes
was determined (supplemental Fig. S3 and the key features of
the SILAC analyses are summarized in supplemental Table
S3).
A SILAC ratio representing the fold change of protein abun-
dance after individually silencing 65 TKs was compared and
normalized to control group (siControl). After normalization,
values of fold changes are all above 0, with value 1 (0 on the
log2 scale) showing that the expression levels of the specific
proteins are not altered after TKs silencing. To acquire a
portrait of the TK-regulated proteome, the overall pattern of
regulation is shown in the heatmap of quantified values. To
improve resolution and concentrate the plot in the most sig-
nificantly enriched region,1000 identified proteins were pre-
sented. For each knockdown (rows), the quantified values are
plotted in red for down-regulated, white for no-change and
nonidentified and blue for up-regulated proteins (Fig. 2). Fur-
thermore, the SILAC proteomic quantifications also confirmed
the efficient knockdown of the individual TKs and a quantifi-
cation heatmap of cross identification of TKs in all experi-
ments are displayed (supplemental Fig. S4). In some cases,
the silenced TKs proteins were not identified, because of
either innate low abundance or high silencing efficiency,
which did not allow the detection (i.e. EGFR, EPHA1, EPHB2,
EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, JAK1, PTK2B,
PTK7, and YES1). Other strongly down-regulated TKs that
were detected during their silencing include CSK, DDR1,
IGF1R, PTK2, and RET.
Cluster Identification of the TKs in MCF7 Cells—We then
calculated and plotted pairwise distances based on the quan-
tifications of TK-regulated proteomic signatures using cen-
tered Pearson correlation (27). In the correlation heatmap
showing the distance metric between all kinases in our study,
the smaller distances are displayed in purple corresponding
to similar signatures, whereas the longer distances are in
green (Fig. 3). Ten distinctive clusters were obtained, accord-
ing to the similarity of each TK-regulated proteome and the
complete dendrogram is shown with the labels colored for
these clusters (Fig. 4A). The number and a full list of TKs in
each cluster are presented and the color coding of the clus-
ters is used throughout to identify the analysis relevant to the
corresponding clusters (Fig. 4B).
Characterization of a Proteomic Signature and Functional
Portrait for Each TK Cluster—We next investigated the TK-
regulated proteomic changes within each classified cluster in
more detail to delineate the proteomic signature of each clus-
ter. A decent proportion of proteins showed significant quan-
titative change after knockdown of TKs in each cluster (p 
0.05 according to Significance B calculation) (21). A full list of
proteins that are significantly regulated in each cluster is
presented in supplemental Table S4. To characterize the top
hits within each cluster, we firstly filtered the proteins by the
requirement that they should be identified in at least 70% of
the TKs in a cluster. We then selected the proteins that have
a Significant B value of p  0.05 in at least half the cluster
members. A heatmap showing the log2 ratio values of hit
proteins was generated for each cluster and is shown in Fig.
4C and supplemental Fig. S5. Counts of the most significantly
regulated proteins in each cluster are shown in Fig. 4D. All the
subsequent analyses were conducted based on these signif-
icant hits.
To gain insights into the biologic processes distinctively
modulated by each cluster, we identified the top GO catego-
ries to which the differential proteins in each cluster belong.
We ran the GO analysis on cellular components (CC), biologic
processes (BP) and molecular function (MF). Overall, the iden-
tified proteins are scattered in a variety of cellular compo-
nents, including extracellular matrix, cell membrane, cyto-
plasm, nuclei, synapse, and other organelles. They are
involved in a wide range of cellular activities such as immune
system process, reproduction, metabolic process, growth,
cell communication, development, cell cycle, transcription,
and apoptosis, whose deregulation can contribute to onco-
genesis (Fig. 5A).
The GO analysis of molecular functions showed a large
percentage of proteins with binding, catalytic, structural, and
enzyme regulatory activities within each cluster (Fig. 5B). This
supports the established role of TKs as important modulators
in signal transduction via functional and physical protein–
protein interactions. In addition, the comparative abundance
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of genes provides a high-level functional signature for the
clusters. We thus sought to integrate the GO analyses with the
STRING database to delineate the enrichment of functional
protein–protein interaction networks in each cluster (30). First,
we identified GO terms that were over-represented in the
differential proteins of each cluster. We then depicted the
STRING network for the differential proteins within an over-
represented GO term. Color-coded networks were generated
to distinguish up- (lighter) or down-regulation (brighter) of
proteins. As expected, comprehensively integrated subnet-
works emerged in a functional linked manner. The subnet-
works from each cluster uncovered an exclusive feature of
functional connections contributed by the regulated proteome
and also highlighted the complexities of TK-modulated cellu-
lar signaling. Representatives of the most enriched functional
networks within each cluster are displayed (Fig. 6): in cluster
1, development; in cluster 2, response to cytokine; in cluster
3, immune response; in cluster 4, response to hormone; in
cluster 5, catabolic process and RNA transport; in cluster 6,
cell motility; in cluster 7, metabolic process; in cluster 8, DNA
replication; in cluster 9, protein localization; in cluster 10, cell
death.
Instead of structural homology, our classification highlights
similarity in biologic function and signaling networks shared
FIG. 2. Heatmap of quantified proteins after TK silencing. The overall pattern of regulation is shown in the heatmap of quantified values.
After normalized to siControl, values of fold changes are all above zero, with value one showing that the expression levels of the specific protein
are not altered after silencing TKs. For each knockdown (rows) the quantified value for an identified protein is plotted in red for down regulated
proteins (below one), white for nondifferential and nonidentified and blue for up-regulated proteins (above one). The row labels indicate the
knock out experiment and the colors correspond to the clusters described below.
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among TKs in different clusters. Significantly, this clustering
verifies current knowledge of the recognized functions of
TKs, and also indicates the potential involvement of TKs in
undocumented biologic processes, which merits further in-
vestigation. For example, the most significantly enriched
functional network related to the kinases in cluster 6
(ERBB4, LMTK3, MATK, ROR2, TYRO3, ZAP70) is cell mo-
tility. We have recently shown that lemur receptor tyrosine
kinase 3 (LMTK3) promotes invasion in breast cancer
through GRB2-mediated induction of integrin family mem-
bers, supporting our data presented here (19, 34). Another
good example is manifested in cluster 8, which comprises
JAK1, LCK, and PTK2. In this study, the bioinformatics
analysis revealed a key characteristic of cluster 8 that is its
contribution to DNA replication initiation and elongation
during cell cycle through regulating minichromosome main-
tenance (MCM) proteins (MCM2–7) (Fig. 6), whose deregu-
lation is associated with genomic instability and cancer
(35–38). Our SILAC proteomic data showed that, upon si-
lencing of the three kinases in cluster 8, protein levels of all
MCM members were decreased, which would subsequently
lead to an inhibition in uncontrolled DNA replication in can-
cer. Ultimately, silencing TKs can block sustained replica-
tive immortality of tumor cells. This finding is consistent with
FIG. 3. Correlation heatmap of the distance metric between all 65 TKs in MCF7 cells. Pairwise distances were calculated and plotted
according to the quantifications of TK-regulated proteomic signatures using centered Pearson correlation. In the correlation heatmap showing
the distance metric between all kinases in our study, the smaller distances are displayed in purple, whereas the longer distances are in green.
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the current perceptions of TKs, being oncogenic therapeutic
targets in cancer.
Utilization of the TKs Proteomic Repertoire for Designated
Analyses—To show a broader significance of our proteomic
database in studying the downstream effects and associated
signaling modulated by TKs, two representative example
analyses were performed. Firstly, to investigate the effect of
knockdown of TKs belonging to the same cluster on com-
mon transcription factors (TFs), we utilized a repertoire of
1391 TFs previously identified (39). A total of 221 TFs were
quantified in at least one SILAC knockdown experiment in
our data set and 73 common TFs were quantified in a
minimum of 55 knockdowns. We clustered the TFs accord-
ing to their values in our experiments upon individual TK
knockdown. We then plotted the SILAC proteomic meas-
urements of these TFs against the TKs (supplemental Fig.
S6). Importantly, the clusters identified by the proteomic
data indicate new functional relationships among transcrip-
tion factors. For instance, the regulation pattern of different
TFs, such as LARP1, CUL2, and TCF25, by the TKs is
consistently observed in the data set, highlighting a poten-
tial similarity in their biological function. Furthermore, we
also saw consistent patterns of coregulation of TFs by
different cluster members. For example, cluster 6 (black)
shows a strong pattern throughout the whole TFs, whereas
there is a marked up-regulation of SSRP, UBTF, and PREX1
in cluster 2 (red). The new grouping of TFs shows a broad
regulation pattern of TFs by different kinases in the same
cluster, suggesting various cross-talks between TFs and
TKs, as well as between members within each family.
FIG. 4. Hierarchical clustering of the 65 TKs expressed in MCF7 cells. A, Hierarchical clustering of the 65 TKs was performed using R’s
hclust function. The complete linkage method which aims to identify similar clusters based on overall cluster measure was used. Ten distinctive
clusters were obtained and the complete dendrogram is shown with the labels colored for these clusters. B, Full list of the TKs included in each
cluster . The color-coding of the clusters is used throughout to identify the analysis relevant to the corresponding clusters. C, Heatmap of the
proteomic quantifications (log2 values of normalized fold changes against control) for the downstream effects (significantly up- or down-
regulated proteins, Significant B test p 0.05) after silencing TKs in cluster 1. D, Number of proteins significantly up or down-regulated in each
identified cluster. x axis shows 10 different clusters and y axis indicates the counts.
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We also present another example exploiting the effect of
TKs knockdowns on proteins involved in translation initiation.
We then mapped the overall regulation of eukaryotic transla-
tion initiation factors (EIFs) by TKs in our data set. Forty-two
EIFs were quantified and a hierarchical grouping of the EIFs
family was generated (supplemental Fig. S7). Moreover, our
analysis revealed interesting functional connections among
EIFs modulated by TKs. For instance, EIF4A1, EIF4B, and
EIF3I were affected in a similar way by the majority of the TKs,
although they have not been linked functionally before. Our
results indicate an essential role of TKs in regulating the
initiation of protein synthesis, but the related biological inter-
pretation requires further investigation.
The Clinical Significance of Each Classified TK Cluster in
Different Molecular Subtypes of Breast Cancer—Breast can-
cer is a heterogeneous disease with certain subtypes having
better outcomes than others (40). The main molecular sub-
types defined by gene expression profiling include luminal A,
luminal B, basal-like, HER2-enriched, and normal-like (41–
43). To further uncover the association of gene expression
levels of our identified clusters with clinical outcome in differ-
ent subtypes, we utilized the online survival analysis tool KM
Plotter, which has massive gene expression data and survival
information derived from more than 3000 patients from data-
bases including The Cancer Genome Atlas (TCGA) (33). Con-
sidering that the MCF7 cell line belongs to the luminal sub-
type, the relevance of the mean expression levels of various
TKs in each classified cluster on relapse free survival (RFS) in
luminal A and luminal B breast cancer was assessed (Fig. 7A
and supplemental Fig. S8). Our results showed a distinctive
correlation for each cluster with survival time in different sub-
types of breast cancer. For example, in cluster 1, the higher
average expression levels of ABL1, AXL, EPHA2, EPHA4,
LMTK2, MST1R, NTRK1, and RYK associated with a longer
RFS in luminal A and luminal B patients, whereas the lower
average expression levels of cluster 5 (EPHB3 and ERBB2) or
cluster 10 (LYN, STYK1, and TNK2) genes correlated with a
longer RFS in luminal B and luminal A subtypes respectively.
This further confirms that breast cancer represents a diverse
spectrum of diseases with distinct biologic features and var-
ied clinical outcome. In many cases, predictive or prognostic
significance to survival cannot be simply attributed to single
markers. Conversely, our identified TK clusters revealing
complex molecular signatures and biologic functions might
serve as complementary panel biomarkers to the known es-
tablished ones, such as ER and PgR, to have prognostic and
therapeutic implications.
Profile of Each Classified TK Cluster for Drug Sensitivity and
Resistance in Breast Cancer Cell Lines—Aberrant regulations
of genes or proteins (including mutations, amplification, and
overexpression) are known to contribute to sensitivity or re-
sistance of cancer cells to therapeutic drugs (32, 44). To
FIG. 5. Characterization of a functional portrait for each cluster. A, A functional profile of top GO biologic processes that the up- and
down-regulated proteins belong to is presented. x axis shows the percentage of hits in each cluster that belong to a GO biologic process term.
The color coding and the number for each cluster are indicated as above. B, A functional profile of top GO molecular functions that the up-
and down-regulated proteins belong to is presented. x axis shows the percentage of hits in each cluster that belong to a GO molecular function
term.
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address whether our established TK clusters could be used to
predict the therapeutic effectiveness in response to drugs in
breast cancer, we integrated the transcriptome data repre-
senting the mRNA expression from the CCLE (31) and doxo-
rubicin-response signature from the GDSC (32). We initially
sought to identify genes correlated to sensitivity/resistance to
doxorubicin and then established the TK clusters significantly
regulating these genes.
Expression values from CCLE for the genes that are most
differentiated in each cluster in our data set were regressed
against the GDSC IC50 values for doxorubicin for a panel of
breast cancer cell lines (37 cell lines, linear regression with
ANOVA p  0.01). In aggregate, our analysis revealed a total
of 15 genes that are significantly associated with sensitivity/
resistance to doxorubicin, which belong to eight TK clusters
(Fig. 7B). In some instances, the identified genes have al-
ready been shown a potential value for assessing response
to cancer treatment, such as neuroblast differentiation-as-
sociated protein (AHNAK) and H2A histone family, member
X (H2AX). For example, two recent studies have reported a
significant gene-drug correlation between AHNAK expression
and chemotherapy compounds, including paclitaxel, docetaxel,
erlotinib, everolimus, and doxorubicin in breast cancer (45, 46).
In addition, several lines of evidence have supported an impor-
tant role of H2AX as a biomarker of drug effect in solid tumors,
including breast and lung cancer (47–49).
FIG. 6. Representatives of defined functional networks in each classified TK cluster. The functional networks were generated using GO
analysis combined with the STRING platform. Proteins in lighter color are up-regulated, whereas brighter color indicates down-regulation.
Arrows show the interactions between connected proteins. Representative defined functional networks associated with their clusters are
shown here. The color coding and the number for each cluster are indicated as above.
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On the other hand, some genes identified above have not
yet been related with drug resistance in cancer. For instance,
protein kinase C and casein kinase substrate in neurons
(PACSIN2) has been documented as a regulator in cell
spreading and migration through interacting with Rac1 and an
important modulator in EGFR internalization (50, 51). Ring
finger protein 213 (RNF213) has been reported as a fusion
partner of ALK and MYC in anaplastic large cell lymphoma
and inflammatory myofibroblastic tumor (52, 53).
Of note, as shown in Fig. 7B, our results showed that
multiple genes from clusters 3 and 5 confer resistance
whereas genes from clusters 2 and 6 primarily confer sensi-
tivity. Furthermore, our analysis showed that numerous iden-
tified genes belong to more than one cluster (i.e. RNF213 is
regulated by TK clusters 1, 3, and 7). These findings reveal a
link between our clusters with doxorubicin response and high-
light again that TKs from different clusters can compensate
for each other through governing same downstream targets.
Further investigation and validation of these new targets in
regulating drug resistance is urgently needed and will ad-
vance our understanding in this field.
DISCUSSION
SILAC coupled to high-resolution MS is shown here and by
other studies to be a simple yet powerful method for investi-
gating the dynamics of protein abundance and post-transla-
tional modifications (4–8). Here, we describe the global
mapping of the TK-regulated proteome and the signaling
dynamics using a high throughput RNAi screen combined
with SILAC-based quantitative proteomics in MCF7 cancer
cells.
Most early studies have focused on elucidating the function
of individual member within the TK family in cancer; different
papers are hard to compare because of the use of different
FIG. 7. Associations of each classified TK with clinical outcomes and drug response in breast cancer. A, Clinical significance of
classified TK clusters in different molecular subtypes of breast cancer. Kaplan-Meier curves showing associations of expression levels of
TKs in cluster 1 with relapse free survival (RFS) in luminal A and luminal B breast cancer were presented. B, Heatmap for the associations
of each classified TK cluster with drug sensitivity and resistance in breast cancer cell lines. Gene expressions of downstream effects (up-
and down-regulated) in each cluster were gained from CCLE and regressed against the GDSC IC50 values for doxorubicin in breast cancer
cell lines. The genes those were most significantly associated with sensitivity (yellow)/resistance (purple) to doxorubicin are presented here
(linear regression with ANOVA p  0.01). The color coding and the number for each cluster are indicated as above.
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cell lines and conditions and in addition, only a few TKs have
been thoroughly studied. A global functional analysis of the
TK regulated-proteome has been, until now, lacking (18). With
recent progress in global quantitative proteomics, this large-
scale, robust identification of biochemical networks impli-
cated in cancer is now feasible (3), as we have shown. We
believe that a complete proteomic portrait provides new val-
uable insights at a global level.
A new classification of the TK family was established con-
taining 10 distinctive clusters based on similarity of the regu-
lated proteome, highlighting a functional redundancy between
various TKs within specific clusters. This new TK-grouping
also offers a possible explanation to the failure of single
TK-targeted therapy, as certain members of a specific group
may compensate for the down-regulation or loss of other
members in the same group. The clustering presented herein
differs to the canonical classification of TKs, although in some
cases the two classifications are in agreement. As expected,
the number of TKs in each of the 10 clusters varies signifi-
cantly, with 15 in the largest group and only two in the small-
est one. This variation might indicate that in the larger families,
TKs tend to function cooperatively to regulate signaling path-
ways, whereas in the smaller groups TKs are more likely to act
alone.
Our analyses uncovered numerous significantly modulated
proteins, most of which are unique in each cluster. A distinc-
tive signature for regulated proteins in each group was de-
rived. In general, identified proteins appear widely distributed
across different cellular compartments and are implicated in
multiple biological processes with dysregulation of these con-
tributing to tumorigenesis. Further combined analyses with
the STRING database showed a clear picture of integrated
functional protein–protein interaction networks modulated by
the TK proteome. GO analysis revealed that although each
cluster has a unique functional signature, there is also some
functional overlap between clusters. This further supports the
notion that TKs in different clusters can contribute to the
activation of the same pathways and compensate for each
other through signaling cross-talk.
Our clustering also suggests the participation of TKs in
undocumented biological processes that await further inves-
tigation. In one example, functional analysis of the proteome
modulated by JAK1, LCK, and PTK2 suggests their involve-
ment in DNA replication through governing the MCM protein
family (35–38). Silencing of these kinases in cluster 8 caused
reduced protein levels of all detected MCM protein members.
This may result in inhibition of sustained replicative immortal-
ity of tumor cells, which supports current opinions that TKs
are tumorigenic and can represent therapeutic targets in can-
cer. Moreover, we present two examples analyzing the regu-
lation pattern of the TFs and EIFs family by TKs to show the
broader significance of our data set.
Additionally, we reveal a distinct association for each clus-
ter with relapse free survival in different molecular subtypes of
breast cancer. It would be intriguing to incorporate our clas-
sified clusters with the established biomarkers to add prog-
nostic and predictive information for patients with different
subtypes of breast cancer. Finally, we observed interesting
links between our TK clusters and a number of genes/proteins
implicated in doxorubicin sensitivity.
To fully interpret the data from SILAC proteomics, further in
vitro and in vivo studies are required to investigate the most
enriched functional networks in each cluster. It would be of
interest to characterize and compare the TK-regulated phos-
pho-proteomic profile using a similar strategy. Notably, global
proteomic analysis that can complement genomic studies can
help us study cellular regulation such as protein interaction,
and can uncover novel mechanisms contributing to tumor
progression (12, 54).
In conclusion, this is the first global proteomic signature of
TKs in breast cancer and a valuable resource for studying the
function of TKs in cancer. Of note, TKs can compensate for
each other to maintain functional activity upon disruption and
can contribute to the same downstream signaling in tumor
initiation and development. We offer an explanation for the
observed resistance to TK-targeted inhibitors considering the
plasticity and reciprocity between TKs. Our data also reveals
a distinct association for each cluster with survival in breast
cancer. It emphasizes a rationale for the development of a
combination of multitargeted TKs as antitumor drugs. Further-
more, we uncover several biochemical networks that will help
us further understand and elucidate the cross-talk between
cellular signaling pathways implicated in breast cancer.
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